Last updated on September 2018

A Study of the Efficacy and Safety of Upadacitnib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional Therapies But Have Not Failed Biologic Therapy


Brief description of study

The objective of this study is to evaluate the efficacy and safety of upadacitinib compared to placebo as induction therapy in participants with moderately and severely active Crohn's disease (CD).

Clinical Study Identifier: NCT03345849

Contact Investigators or Research Sites near you

Start Over

ABBVIE CALL CENTER

Scott Schulman medicine profes /ID# 169066
North Bay, ON Canada
0.89miles
  Connect »